AstraZeneca Says US Court Dismissed Lawsuit Without Prejudice Against FDA

AstraZeneca Closes Patient Enrollment Four Months Ahead Of Plan In EUCLID Study

AstraZeneca Sells Alderley Park Site In Cheshire

AstraZeneca: FDA Approves Bydureon Pen In Adults With Type 2 Diabetes

AstraZeneca Says FDA Approves Orphan Drug Myalept - Quick Facts

Trade AZN now with

3/26/2012 2:12 AM ET

AstraZeneca Plc (AZN: Quote,AZN.L) said that the US District Court denied the company's request for a preliminary injunction application against the FDA and dismissed the lawsuit without prejudice.

On March 23, the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the FDA regarding final marketing approval of generic quetiapine.

Notwithstanding the Court's decision, the company continues to believe strongly in the merits of its position and is evaluating its options.

Click here to receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 43 Articles

Editors Pick

Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary

After turning in a strong performance last week, stocks may show a lack of direction in early trading on Monday. The major index futures are currently pointing to a roughly flat open for the markets, with the Dow futures down by just 1 point.

Kimberly-Clark Q1 Profit Rises, Adj. EPS Tops View; Backs 2014 Adj. EPS Outlook

Healthcare products maker Kimberly-Clark Corp. (KMB) said that its first-quarter net income attributable to the company rose to $538 million from the prior year's $531 million, with earnings per share improving to $1.41 from $1.36 last year. Adjusted earnings for the quarter were $1.48 per share,...

AMD Posts Narrower Loss

Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.